The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC
Open accessAbstract
The success of antimicrobial therapy is determined by complex interactions between an administered drug, a host, and an infecting agent. In a clinical situation, the complexity of these interactions is usually reflected by a high variability in the dose-response relationship. Therefore, to minimize the dose-response variability, key characteristics of the drug, the infecting agent and the host have to be taken into account for selecting an appropriate antibiotic and an appropriate dose. Failure to do so may result in either therapeutic failure or emergence of resistant strains. To date, dose and drug selection is mostly based on a static in vitro parameter, the MIC and on the drug′s serum concentration as a pharmacokinetic parameter. In practice, however, a pharmacodynamic effect in vivo is rather the result of a dynamic exposure of the infective agent to the unbound antibiotic drug fraction at the relevant effect site. Thus, static conditions in an in vitro setting hardly reflect a dynamic situation in a target organ under in vivo conditions. Furthermore, serum concentrations do not reflect the unbound concentrations at the target site. In recent years substantial efforts were devoted to systematically elucidate the dynamic relationship between pharmacokinetic and pharmacodynamic variables. The main concept of this pharmacokinetic-pharmacodynamic approach is to use the concentration-effect relationship of the drug of interest in dosage adjustment and product development in a logical way and minimize trial-and-error approaches (29, 80). This approach can potentially result in substantial savings of time and expenses and may help to avoid unnecessary and, hence, unethical clinical studies (97). Thus, dosages and dosing intervals of antimicrobial agents should be designed with reference to dynamic pharmacokinetic and pharmacodynamic parameters. Accordingly, several efficacy indices or surrogate markers that take into account both pharmacokinetic and pharmacodynamic information have been defined and used by different authors to describe the antibacterial activity of various classes of antimicrobial agents (100, 106, 59). Currently there are two main trends for antibiotic pharmacokinetic-pharmacodynamic models; those based on the MIC and those based on a kill-curve approach, both of which will be described in detail in the following.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Craig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618
The Pharmacodynamics of β‐Lactams
Turnidge, J. D. (1998) · Clinical Infectious Diseases · doi:10.1086/514622 · Cited by 593
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435
Eagle, H., & Musselman, A. D. (1948) · Journal of Experimental Medicine · doi:10.1084/jem.88.1.99 · Cited by 375
Hyatt, J. M., McKinnon, P. S., Zimmer, G. S., & Schentag, J. J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00005 · Cited by 374
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives
Derendorf, H., & Meibohm, B. (1999) · Pharmaceutical Research · doi:10.1023/a:1011907920641 · Cited by 352
Self-citationCiofu, O. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.9 · Cited by 312
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm, B., & Derendorf, H. (1997) · PubMed · Cited by 276
Self-citationPharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
Craig, W. A., Redington, J., & Ebert, S. C. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.suppl_c.29 · Cited by 238
Vancomycin Penetration Into Biofilm Covering Infected Prostheses And Effect On Bacteria
Darouiche, R. O., Dhir, A., Miller, A. J., Landon, G. C., Raad, I. I., & Musher, D. M. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/170.3.720 · Cited by 220
Grasso, S., Meinardi, G., De Carneri, I., & Tamassia, V. (1978) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.13.4.570 · Cited by 188
Boyd, I., & Blatt, J. M. (1988) · Investment Confidence and Business Cycles · doi:10.1007/978-3-642-73118-1_7 · Cited by 163
Jusko, W. J. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600600618 · Cited by 160
Schentag, J. J., Nix, D. E., & Adelman, M. H. (1991) · DICP · doi:10.1177/106002809102501003 · Cited by 141
Löwdin, E., Odenholt, I., & Cars, O. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2739 · Cited by 126
PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTIBIOTICS IN MENINGITIS
Andes, D. R., & Craig, W. A. (1999) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70096-9 · Cited by 122
Reigner, B. G., Williams, P. E. O., Patel, I. H., Steimer, J., Peck, C. C., & van Brummelen, P. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733020-00005 · Cited by 121
In vivo verification of in vitro model of antibiotic treatment of device-related infection
Blaser, J., Vergères, P., Widmer, A. F., & Zimmerli, W. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.5.1134 · Cited by 116
Knudsen, J. D., Fuursted, K., Raber, S. R., Espersen, F., & Frimodt‐Møller, N. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1247-1254.2000 · Cited by 115
Antimicrobial resistance issues of the future
Craig, W. A. (1996) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(96)00162-9 · Cited by 114
Schentag, J. J. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.6.426 · Cited by 103
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats
Thauvin, C., Eliopoulos, G. M., Willey, S., Wennersten, C. B., & Moellering, R. C. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.2.139 · Cited by 97
Chambers, H. F. “., & Kennedy, S. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.4.510 · Cited by 96
BIRKNESS, K. A., Deslauriers, M., Bartlett, J. H., WHITE, E. H., King, C. H., & Quinn, F. D. (1999) · Infection and Immunity · doi:10.1128/iai.67.2.653-658.1999 · Cited by 89
Frimodt-Meller, N., Bentzen, M. W., & Thomsen, V. F. (1986) · The Journal of Infectious Diseases · doi:10.1093/infdis/154.3.511 · Cited by 88
Hyatt, J. M., Nix, D. E., & Schentag, J. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2730 · Cited by 87
Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy
Hoffman, A., & Stepensky, D. (1999) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v16.i6.20 · Cited by 85
Zhi, J., Nightingale, C. H., & Quintiliani, R. (1988) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062551 · Cited by 80
Kutlin, A., Roblin, P. M., & Hammerschlag, M. R. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2268 · Cited by 79
In-vitro evaluation of ampicillin/brobactam and comparison with other β-lactam antibiotics
Melchior, N. H., & Keiding, J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.1.29 · Cited by 71
Craig, W. A. (1995) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01690745 · Cited by 60
McGrath, B. J., Kang, S., Kaatz, G. W., & Rybak, M. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2034 · Cited by 60
Stratton, C. W., Weinstein, M. P., & Reller, L. B. (1982) · The Journal of Infectious Diseases · doi:10.1093/infdis/145.2.160 · Cited by 58
Corvaisier, S., Maire, P. H., dʼYvoire, M. J. Y. B., Barbaut, X., Bleyzac, N., & Jelliffe, R. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1731 · Cited by 54
Pharmacodynamic Interactions of Antibiotics Alone and in Combination
Schentag, J. J., Strenkoski‐Nix, L. C., Nix, D. E., & Forrest, A. (1998) · Clinical Infectious Diseases · doi:10.1086/514621 · Cited by 52
Gengo, F. M., Mannion, T. W., Nightingale, C. H., et al. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.6.619 · Cited by 49
Mentec, H., Vallois, J. M., Buré, A., Saleh‐Mghir, A., Jehl, F., & Carbon, C. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.1883 · Cited by 46
Mordenti, J. J., Quintiliani, R., & Nightingale, C. H. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.suppl_a.313 · Cited by 46
Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections
Onyeji, C. O., Nicolau, D. P., Nightingale, C. H., & Quintiliani, R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.5.1112 · Cited by 44
Bellido, F., Pechère, J. C., & Hancock, R. E. W. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.68 · Cited by 40
Antibiotic Cycling: Is It Ready for Prime Time?
John, J. F. (2000) · Infection Control and Hospital Epidemiology · doi:10.1086/501689 · Cited by 39
Bergan, T., & Carlsen, I. B. (1980) · Infection · doi:10.1007/bf01644943 · Cited by 19
Odenholt-Tornqvist, I. (1988) · Scandinavian Journal of Infectious Diseases · doi:10.3109/inf.1988.20.suppl-58.01 · Cited by 16
Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy
Moise, P. A., & Schentag, J. J. (1998) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-199812000-00005 · Cited by 8
Cited by
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
The world of subinhibitory antibiotic concentrations
Davies, J., Spiegelman, G. B., & Yim, G. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.006 · Cited by 750
Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods
Gajic, I., Kabic, J., Kekic, D., Jovicevic, M., Milenkovic, M., Mitic Culafic, D., Trudic, A., Ranin, L., & Opavski, N. (2022) · Antibiotics · doi:10.3390/antibiotics11040427 · Cited by 557
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 475
Self-citationPharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Self-citation
Metadata
- Authors
- Mueller, M., de la Peña, A., & Derendorf, H.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-02
- Volume
- 48
- Issue
- 2
- Pages
- 369-377
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2129122463
- Cited by
- 304
- References
- 52
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.